Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Sun Pharmaceutical Industries Ltd.
  6. News
  7. Summary
    SUNPHARMA   INE044A01036


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

India COVID cases hold close to record highs as calls widen for national lockdown

05/10/2021 | 01:01am EDT

* Past 24 hours see 366,161 new infections and 3,754 deaths

* Cases off peak, but testing numbers also down

* Pressure grows for nationwide shutdown

NEW DELHI, May 10 (Reuters) - Indian coronavirus infections and deaths held close to record daily highs on Monday, increasing calls for the government of Prime Minister Narendra Modi to lock down the world's second-most populous country.

The 366,161 new infections and 3,754 deaths reported by the health ministry were off a little from recent peaks, taking India's tally to 22.66 million with 246,116 deaths as hospitals run out of oxygen and beds and morgues and crematoria overflow. (Graphic on global cases and deaths) https://tmsnrt.rs/34pvUyi

Experts have said India's actual figures could be far higher than reported.

Sunday's 1.47 million tests for COVID-19 were this month's lowest yet, data from the state-run Indian Council of Medical Research showed. The figure compared with a daily average of 1.7 million for the first eight days of May.

The number of positive results from the tests was not immediately clear, however.

Many states have imposed strict lockdowns over the last month while others have placed curbs on movement and shut cinemas, restaurants, pubs and shopping malls.

But pressure is mounting on Modi to announce a nationwide lockdown as he did during the first wave of infections last year.

He is battling criticism for allowing huge gatherings at a religious festival and holding large election rallies during the past two months even as cases surged.

"A failure of governance of epic and historic proportions," Vipin Narang, a political science professor at the Massachusetts Institute of Technology (MIT) in the United States, said on Twitter.

Sonia Gandhi, the chief of the main opposition Congress party, blamed the government for abdicating its responsibility by leaving vaccinations to states, Reuters partner ANI said on Twitter.

Delhi's health minister said the city was running out of vaccines, with just three to four days of supplies remaining of AstraZeneca, made by the Serum Institute of India and branded Covishield, the NDTV news channel reported.

By Monday, the world's largest vaccine-producing nation had fully vaccinated just over 34.8 million, or about 2.5%, of a population of about 1.35 billion, government data shows. (Graphic on global vaccinations) https://tmsnrt.rs/3tUM8ta


On Sunday, top White House coronavirus adviser Dr. Anthony Fauci said he had advised Indian authorities they needed to shut down.

"You’ve got to shut down," Fauci said on ABC's "This Week" television show. "I believe several of the Indian states have already done that, but you need to break the chain of transmission. And one of the ways to do that is to shut down."

The Indian Medical Association (IMA) has also called for a "complete, well-planned, pre-announced" lockdown.

New Delhi entered a fourth week of lockdown, with tougher curbs such as the shutdown of the suburban rail network, while residents scrambled for scarce hospital beds and oxygen supplies.

"This is not the time to be lenient," Delhi chief minister Arvind Kejriwal said on Sunday.

"This phase is so tough, this wave is so dangerous, so many people are dying...the priority at this hour is to save lives," he said in a televised address.

Late on Sunday, the northern state of Uttarakhand said it would impose curfew from Tuesday until May 18, just days after mass religious gatherings held in the state became virus super spreading events.

Shops selling essential food items will stay open for some hours in the morning, while malls, gyms, theatres, bars and liquor shops are among the enterprises that will be shut, the government said.

Organisers of the popular and lucrative Indian Premier League (IPL) cricket tournament conceded the remaining games would have to be played overseas after having suspended the contest over the virus this month.

Global support, in the form of oxygen cylinders and concentrators, ventilators and other medical gear, has poured in.

U.S. company Eli Lilly and Co said it had signed licensing deals with Indian drugmakers, such as Cipla Ltd , Lupin and Sun Pharma to make and sell its arthritis drug baricitinib for the treatment of COVID-19 patients.

India's drug regulator has approved the drug for restricted emergency use in combination with remdesivir for hospitalised adult sufferers requiring oxygen.

(Reporting by Anuron Kumar Mitra in Bengaluru, Tanvi Mehta, Neha Arora and Amlan Chakraborty in New Delhi, Saurabh Sharma in Lucknow; Writing by Lincoln Feast; Editing by Clarence Fernandez and Nick Macfie)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.02% 8337 Delayed Quote.13.98%
CIPLA LIMITED -0.44% 972.5 Delayed Quote.18.04%
SUN PHARMACEUTICAL INDUSTRIES LTD. -0.04% 677.5 Delayed Quote.15.02%
06/03MEDULLOBLASTOMA PIPELINE : Emerging Therapies and Key pharma players involved by..
06/02SUN PHARMACEUTICAL INDUSTRIESá : to Launch Swiss Pharma's Postpartum Hemorrhage ..
05/28Indian Stocks End in Green on Friday; Reliance Industries Rallies 6%
05/27SUN PHARMACEUTICAL INDUSTRIES'á : Consolidated Profit More than Doubles in Fisca..
05/19Indian Stocks Snap Winning Streak on Wednesday; Tata Motors Slumps Over 5%
05/10Indian Stocks Maintain Four-Day Winning Streak on Monday; Larsen and Toubro R..
05/10Indian shares settle up as record high commodity prices lift metal stocks
05/10India COVID cases hold close to record highs as calls widen for national lock..
05/09Eli Lilly signs deals to boost supply of COVID-19 treatment in India
More news
Sales 2021 339 B 4 632 M 4 632 M
Net income 2021 37 004 M 505 M 505 M
Net cash 2021 58 736 M 802 M 802 M
P/E ratio 2021 37,3x
Yield 2021 0,49%
Capitalization 1 625 B 22 201 M 22 192 M
EV / Sales 2021 4,62x
EV / Sales 2022 4,11x
Nbr of Employees 36 000
Free-Float 82,7%
Duration : Period :
Sun Pharmaceutical Industries Ltd. Technical Analysis Chart | SUNPHARMA | INE044A01036 | MarketScreener
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 736,34 INR
Last Close Price 677,10 INR
Spread / Highest target 25,5%
Spread / Average Target 8,75%
Spread / Lowest Target -22,5%
EPS Revisions
Managers and Directors
Dilip Shantilal Shanghvi Managing Director & Executive Director
C. S. Muralidharan Chief Financial Officer
Israel Makov Non-Executive Chairman
Atanu Roy SVP & Chief Information Officer
Ashok I. Bhuta Compliance Officer & Senior GM-Secretarial
Sector and Competitors